DUSP6 and breast carcinoma: To understand whether nuclear DUSP6 is associated with drug resistance, we next examined DUSP6 expression in the 4T1 TNBC metastatic mouse breast cancer model treated with control vehicle, Abraxane (nab-paclitaxel, 30 mg/kg), or anti-PD1 (RMP1–14, 10 mg/kg) using the ASI digital pathology system.